PRE-TREATMENT IP-10 LEVELS AND IL28B GENOTYPE IN PREDICTION OF SVR IN PRIOR TREATMENT-EXPERIENCED GENOTYPE 1 HCV PATIENTS TREATED WITH TELAPREVIR/PEGINTERFERON/ RIBAVIRIN IN THE REALIZE STUDY

被引：2
|
作者：
Vijgen, L. [1 ]
Talloen, W. [2 ]
Scholliers, A. [1 ]
Johansson, S. [1 ]
Tuefferd, M. [2 ]
De Meyer, S. [1 ]
Witek, J. [3 ]
Fanning, G. [1 ]
Picchio, G. [3 ]
Pol, S. [4 ,5 ]
Zeuzem, S. [6 ]
Aerssens, J. [1 ]
机构：
[1] Tibotec BVBA, Beerse, Belgium
[2] Janssen Res & Dev, Beerse, Belgium
[3] Janssen Res & Dev LLC, Titusville, NJ USA
[4] Univ Paris 05, INSERM, U1016, Paris, France
[5] Cochin Hosp, Assistance Publ Hop Paris, Paris, France
[6] Goethe Univ Frankfurt, Med Ctr, Frankfurt, Germany
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)61179-9
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1167
引用
收藏
页码：S462 / S462
页数：1
相关论文
共 50 条
  • [1] Pre-treatment IP-10 levels and IL28B genotype as predictive markers for SVR in treatment-naive patients with genotype 1 HCV infection treated with telaprevir/peginterferon/ribavirin in the OPTIMIZE study
    Vijgen, Leen
    Dierynck, Inge
    Janssen, Katrien
    Talloen, Willem
    Gys, Luc
    Vanhoof, Greet
    Luo, Donghan
    De Meyer, Sandra
    Witek, James
    Aerssens, Jeroen
    HEPATOLOGY, 2013, 58 : 1096A - 1097A
  • [2] IMPACT OF IL28B GENOTYPE AND PRETREATMENT SERUM IP-10 IN TREATMENT-NAIVE GENOTYPE-1 HCV PATIENTS TREATED WITH TMC435 IN COMBINATION WITH PEGINTERFERONα-2A AND RIBAVIRIN IN PILLAR STUDY
    Aerssens, J.
    Fanning, G.
    Scholliers, A.
    Lenz, O.
    Peeters, M.
    De Smedt, G.
    Fried, M.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S5 - S6
  • [3] IMPACT OF ANEMIA AND RIBAVIRIN DOSE REDUCTION ON SVR TO A TELAPREVIR-BASED REGIMEN IN PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE IN THE PHASE III REALIZE STUDY
    Roberts, Stuart K.
    Andreone, Pietro
    Pol, Stanislas
    Younossi, Zobair M.
    Diago, Moises
    Lawitz, Eric
    Focaccia, Roberto
    Foster, Graham R.
    Horban, Andrzej
    Lonjon-Domanec, Isabelle
    DeMasi, Ralph
    van Heeswijk, Rolf
    Picchio, Gaston
    Witek, James
    Zeuzem, Stefan
    HEPATOLOGY, 2011, 54 : 1007A - 1008A
  • [4] Combination of Vaniprevir With Peginterferon and Ribavirin Significantly Increases the Rate of SVR in Treatment-Experienced Patients With Chronic HCV Genotype 1 Infection and Cirrhosis
    Rodriguez-Torres, Maribel
    Stoehr, Albrecht
    Gane, Edward J.
    Serfaty, Lawrence
    Lawitz, Eric
    Zhou, Amy
    Bourque, Michael
    Bhanja, Sanhita
    Strizki, Julie
    Barnard, Richard J. O.
    Hwang, Peggy M. T.
    DiNubile, Mark J.
    Mobashery, Niloufar
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2014, 12 (06) : 1029 - +
  • [5] Characterization of resistant variants in treatment-experienced genotype-1 HCV patients receiving telaprevir/peginterferon/ribavirin in Phase II clinical trials
    Bartels, D. J.
    Sullivan, J. C.
    Zhang, E. Z.
    Tigges, A. M.
    Dorrian, J. L.
    Kwong, A. D.
    Kieffer, T. L.
    ANTIVIRAL THERAPY, 2010, 15 : A29 - A29
  • [6] Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure
    Pol, Stanislas
    Aerssens, Jeroen
    Zeuzem, Stefan
    Andreone, Pietro
    Lawitz, Eric J.
    Roberts, Stuart
    Younossi, Zobair
    Foster, Graham R.
    Focaccia, Roberto
    Horban, Andrzej
    Pockros, Paul J.
    Van Heeswijk, Rolf P. G.
    De Meyer, Sandra
    Luo, Don
    Botfield, Martyn
    Beumont, Maria
    Picchio, Gaston
    JOURNAL OF HEPATOLOGY, 2013, 58 (05) : 883 - 889
  • [7] Clinical virology findings from treatment-naive and treatment-experienced genotype 1 HCV patients receiving telaprevir/peginterferon/ribavirin in Phase 3 clinical trials
    Kieffer, T. L.
    De Meyer, S.
    Bartels, D. J.
    Sullivan, J. C.
    Dierynck, I.
    Adda, N.
    Kwong, A.
    Jacobson, I. M.
    Sherman, K. E.
    Zeuzem, S.
    Picchio, G.
    ANTIVIRAL THERAPY, 2011, 16 : A27 - A27
  • [8] RIBAVIRIN MONOTHERAPY REDUCES HCVRNA IN ASSOCIATION WITH IL28B GENOTYPE AND ALSO IP-10 CONCENTRATIONS AMONG PATIENTS INFECTED WITH HEPATITIS C GENOTYPE 1
    Waldenstrom, J.
    Westin, J.
    Nystrom, K.
    Christensen, P.
    Dalgard, O.
    Farkkila, M.
    Lindahl, K.
    Norkrans, G.
    Norrgren, H.
    Buhl, M. R.
    Stenmark, S.
    Lagging, M.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S493 - S493
  • [9] EFFICACY AND SAFETY OF TELAPREVIR-BASED REGIMENS IN CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1 AND PRIOR PEGINTERFERON/RIBAVIRIN TREATMENT FAILURE: SUBANALYSIS OF THE REALIZE PHASE III STUDY
    Pol, Stanislas
    Roberts, Stuart K.
    Andreone, Pietro
    Younossi, Zobair M.
    Diago, Moises
    Lawitz, Eric
    Focaccia, Roberto
    Foster, Graham R.
    Horban, Andrzej
    Lonjon-Domanec, Isabelle
    DeMasi, Ralph
    van Heeswijk, Rolf
    De Meyer, Sandra
    Picchio, Gaston
    Witek, James
    Zeuzem, Stefan
    HEPATOLOGY, 2011, 54 : 374A - 375A
  • [10] Efficacy and safety of telaprevir-based regimens in cirrhotic patients with HCV genotype 1 and prior peginterferon/ribavirin treatment failure: subanalysis of the REALIZE Phase III study
    Roberts, Stuart
    Pol, Stanislas
    Andreone, Pietro
    Younossi, Zobair
    Diago, Moises
    Lawitz, Eric J.
    Focaccia, Roberto
    Foster, Graham R.
    Horban, Andrzej
    Lonjon-Domanec, Isabelle
    Demasi, Ralph
    Heeswijk, Rolf V.
    Meyer, Sandra D.
    Picchio, Gaston
    Witek, James
    Zeuzem, Stefan
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 : 177 - 177
12345